Compare IDEXX Laboratories, Inc. (IDXX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tapestry, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B), while Tapestry, Inc. trades at $153.89 (market cap $32.44B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TPR | |
|---|---|---|
Market Cap | $46.22B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $164.78 |
52-Week Low | $526.44 | $95.69 |
Enterprise Value | $47.12B | $35.29B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
TPR trades at $153.17, down 7.05% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $1.66, beating expectations of $1.30, and maintains robust profitability with a gross margin of 76.18% and ROE of 55.74%. Recent news highlights AI integration efforts and upcoming Q4 earnings on August 13, 2026.
Outlook is positive driven by earnings beats and brand momentum, but risks include high valuation multiples and debt levels. The consensus price target is $190.33, implying significant upside, supported by 75.61% buy ratings from analysts. Investors should monitor Q2 2026 earnings and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
